Strata Skin Sciences, Inc. (NASDAQ:SSKN) Short Interest Up 482.2% in October

Strata Skin Sciences, Inc. (NASDAQ:SSKN) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 1,520,000 shares, a growth of 482.2% from the September 30th total of 261,100 shares. Based on an average trading volume of 4,460,000 shares, the short-interest ratio is presently 0.3 days. Approximately 42.7% of the shares of the company are short sold. Approximately 42.7% of the shares of the company are short sold. Based on an average trading volume of 4,460,000 shares, the short-interest ratio is presently 0.3 days.

Strata Skin Sciences Trading Down 9.8%

Strata Skin Sciences stock opened at $1.74 on Thursday. The stock has a market cap of $9.17 million, a P/E ratio of -0.61 and a beta of 0.50. Strata Skin Sciences has a fifty-two week low of $1.38 and a fifty-two week high of $3.86. The firm’s fifty day moving average price is $1.87 and its 200-day moving average price is $2.17. The company has a debt-to-equity ratio of 49.58, a quick ratio of 0.75 and a current ratio of 0.98.

Strata Skin Sciences (NASDAQ:SSKN) last released its quarterly earnings results on Wednesday, August 13th. The medical device company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.33). The firm had revenue of $7.70 million during the quarter, compared to the consensus estimate of $8.56 million. Strata Skin Sciences had a negative return on equity of 266.94% and a negative net margin of 35.13%. Equities research analysts forecast that Strata Skin Sciences will post -1.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SSKN has been the subject of a number of research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Strata Skin Sciences in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Strata Skin Sciences to a “sell” rating in a research note on Saturday, October 18th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $6.00.

About Strata Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.